823 related articles for article (PubMed ID: 24347316)
21. Real-World Effectiveness of Beta-Blockers versus Other Antihypertensives in Reducing All-Cause Mortality and Cardiovascular Events.
Foch C; Allignol A; Hostalek U; Boutmy E; Hohenberger T
Int J Clin Pract; 2022; 2022():6124559. PubMed ID: 35989866
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin receptor blockers for management of hypertension.
Catanzaro DF; Frishman WH
South Med J; 2010 Jul; 103(7):669-73. PubMed ID: 20531060
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Anti-Hypertensive Therapy and Stroke Prevention: A Meta-Analysis.
Mukete BN; Cassidy M; Ferdinand KC; Le Jemtel TH
Am J Cardiovasc Drugs; 2015 Aug; 15(4):243-57. PubMed ID: 26055616
[TBL] [Abstract][Full Text] [Related]
24. Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.
Sim JJ; Bhandari SK; Shi J; Kalantar-Zadeh K; Rasgon SA; Sealey JE; Laragh JH
Am J Hypertens; 2012 Mar; 25(3):379-88. PubMed ID: 22158065
[TBL] [Abstract][Full Text] [Related]
25. Therapy with renin-angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder?
Berkowitsch A; Neumann T; Kuniss M; Janin S; Wojcik M; Zaltsberg S; Mitrovic V; Pitschner HF
Pacing Clin Electrophysiol; 2010 Sep; 33(9):1101-11. PubMed ID: 20487340
[TBL] [Abstract][Full Text] [Related]
26. Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolic stroke?
Solun B; Marcoviciu D; Dicker D
Eur J Intern Med; 2009 Mar; 20(2):125-31. PubMed ID: 19327599
[TBL] [Abstract][Full Text] [Related]
27. Antihypertensive drug prescribing and persistence among new elderly users: implications for persistence improvement interventions.
Tu K; Anderson LN; Butt DA; Quan H; Hemmelgarn BR; Campbell NR; McAlister FA;
Can J Cardiol; 2014 Jun; 30(6):647-52. PubMed ID: 24882536
[TBL] [Abstract][Full Text] [Related]
28. Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report.
Colvin CL; King JB; Oparil S; Wright JT; Ogedegbe G; Mohanty A; Hardy ST; Huang L; Hess R; Muntner P; Bress A
JAMA Netw Open; 2020 Nov; 3(11):e2025127. PubMed ID: 33206191
[TBL] [Abstract][Full Text] [Related]
29. [The clinical usefulness of RAAS inhibitors in hypertensive patients].
Yamaguchi K; Sata M
Nihon Rinsho; 2012 Sep; 70(9):1571-6. PubMed ID: 23012805
[TBL] [Abstract][Full Text] [Related]
30. [Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
Baumgart P
MMW Fortschr Med; 2008 Jan; 150(1-2):52-3. PubMed ID: 18300647
[No Abstract] [Full Text] [Related]
31. Current status of antihypertensive prescription and associated blood pressure control in Japan.
Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
[TBL] [Abstract][Full Text] [Related]
32. Development and trends in the drug treatment of essential hypertension.
van Zwieten PA
J Hypertens Suppl; 1992 Dec; 10(7):S1-12. PubMed ID: 1363322
[TBL] [Abstract][Full Text] [Related]
33. [Antihypertensive therapy in 357 inpatients of elderly isolated systolic hypertension].
Zhai LH; Yang CY; Jiang KW; Xu XY; Lu HZ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 30(6):719-22, 725. PubMed ID: 16708819
[TBL] [Abstract][Full Text] [Related]
34. [Trends in the use of antihypertensive drugs in France from 2002 to 2012: FLAHS surveys].
Girerd X; Hanon O; Pannier B; Vaïsse B; Mourad JJ
Ann Cardiol Angeiol (Paris); 2013 Jun; 62(3):210-4. PubMed ID: 23759733
[TBL] [Abstract][Full Text] [Related]
35. 50 years of thiazides: should thiazide diuretics be considered third-line hypertension treatment?
Brown A; Captain B
Am J Ther; 2011 Nov; 18(6):e244-54. PubMed ID: 21436766
[TBL] [Abstract][Full Text] [Related]
36. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
Matsuzaki M; Ogihara T; Umemoto S; Rakugi H; Matsuoka H; Shimada K; Abe K; Suzuki N; Eto T; Higaki J; Ito S; Kamiya A; Kikuchi K; Suzuki H; Tei C; Ohashi Y; Saruta T;
J Hypertens; 2011 Aug; 29(8):1649-59. PubMed ID: 21610513
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.
L'Allier PL; Ducharme A; Keller PF; Yu H; Guertin MC; Tardif JC
J Am Coll Cardiol; 2004 Jul; 44(1):159-64. PubMed ID: 15234426
[TBL] [Abstract][Full Text] [Related]
38. Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries.
Htoo PT; Stürmer T; Jonsson-Funk M; Pate V; Simpson RJ; Lund JL
Epidemiology; 2019 Nov; 30(6):867-875. PubMed ID: 31348009
[TBL] [Abstract][Full Text] [Related]
39. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
40. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
